UCB's Global Corporate Website

This section is intended for media and financial analysts

Our Shareholders

Since 13 March 2014, UCB’s capital amounts to € 583 516 974, divided in 194 505 658 ordinary shares with no nominal value.

The main shareholder of UCB is Financière de Tubize SA, a Belgian company listed on Euronext Brussels.

Shareholder Structure

Source

Latest notifications and shareholder identification (as of January 2023), UCB underlying ownership analysis

close

62% Free Float

Institutional investors:
Geographic distribution

Shareholders' Meetings

The Ordinary General Meeting of Shareholders is held on the last Thursday of April at 11:00 CET.

The next shareholders' meeting takes place on

25 April 2024

Shareholders' Meeting Archives


 


 

Consensus

Estimates based on Visible Alpha consensus1 dated 31.08.2023.

Estimates include 11 broker models2.

UCB FY Consensus Earnings Estimates (Average)
In € million 2022a 2023e 2024e 2025e  2026e 2027e 2028e
Net Sales 5,140 4,893 5,463 6,153 6,611 7,048 7,480
Revenue 5,517 5,232 5,742 6,415 6,830 7,238 7,676
Adjusted EBIT 675 577 847 1,356 1,596 1,808 1,951
Adjusted EBITDA 1,260 1,204 1,506 2,048 2,285 2,469 2,599
Adj. EBITDA ratio 22.8% 23.0% 26.2% 31.9% 33.4% 34.1% 33.9%
Net Profit 418 331 562 1,021 1,220 1,369 1,471
Core EPS (€) 4.37 3.67 4.95 7.49 8.45 9.23 9.64
UCB FY Consensus Product Sales Estimates (Average)
In € million 2022a 2023e 2024e 2025e  2026e  2027e  2028e
Product Portfolio              
Cimzia 2,085 2,059 1,974 1,843 1,615 1,350 1,172
Bimzelx 35 182 539 995 1,497 2,029 2,523
Evenity* 25 58 99 131 160 183 203
Rystiggo   20 90 171 271 363 412
Vimpat 1,124 413 337 274 231 207 182
Keppra 729 625 559 515 477 444 419
Briviact 485 567 639 700 520 372 318
Neupro 305 278 246 218 201 186 166
Fintepla 116 233 380 510 627 713 691
Nayzilam 78 99 119 137 145 154 139
Potential New Products non-risk adjusted        
Zilucoplan   24 163 296 500 652 798
Dapirolizumab pegol     25 48 115 206 258
Staccato alprazolam     21 33 73 118 137
Bepranemab         5 120 160
UCB0599         15 40 105
doxTM / MT1621   5 13 38 80 114 122

*European sales, ex-EU sales booked by Amgen/Astellas

1Disclaimer

The information provided by Visible Alpha cited herein provided “as is” and “as available” without warranty of any kind. Use of any Visible Alpha data is at your own risk and Visible Alpha disclaims any liability for use of the Visible Alpha data.
Although the information is obtained or compiled from reliable sources Visible Alpha neither can nor does guarantee or make any representation or warranty, either express or implied, as to the accuracy, validity, sequence, timeliness, completeness or continued availability of any information or data, including third-party content, made available herein.
In no event shall Visible Alpha be liable for any decision made or action or inaction taken in reliance on any information or data, including third-party content. Visible Alpha further explicitly disclaims, to the fullest extent permitted by applicable law, any warranty of any kind, whether express or implied, including warranties of merchantability, fitness for a particular purpose and non-infringement.

close

2Contributing brokers

Broker Model date
Berenberg 01-Aug-2023
BNPP Exane 04-Aug-2023
BofA 28-Jul-2023
Citi 06-Jul-2023
Cowen 27-Jul-2023
Credit Suisse 31-Jul-2023
HSBC 15-Aug-2023
Jefferies 31-Jul-2023
Kepler Cheuvreux 02-Aug.2023
Redburn 17-Aug-2023
UBS 31-Jul-2023

 

close

 

Dividends

The Board intends to continue to sustain a dynamic dividend policy, consistent with the long-term growth prospects of the Company, offering gradual increase in dividend, and as far as possible not to reduce it, irrespective of the short-term income variations.

The Board of Directors proposed to pay a gross dividend of € 1.33 per share (gross), which was approved by the annual general meeting of the shareholders.

  • Coupon # 26
  • Ex-dividend: 28 April 2023
  • Record date: 2 May 2023
  • Payment: 3 May 2023

Coupon # 26 of UCB shares is payable at € 0.931 net per share after deduction of Belgian withholding tax of 30%*, via our paying agent, KBC Bank NV.

* Lower withholding tax rates may be applicable depending on the specific situation of each shareholder.